Condition: Generalized Anxiety Disorder · Sponsor: Reunion Neuroscience Inc
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
This description comes directly from the study's public registry record.
Mark Pollack Chief Medical Officer, M.D. · 1-888-880-REUN · info@reunionneuro.com
Always discuss trial participation with your own doctor first.
| Lighthouse Psychiatry | Gilbert, Arizona, United States | Recruiting |
| Preferred Research Partners, Inc. | Little Rock, Arkansas, United States | Recruiting |
| Collaborative Neuroscience Research, LLC | Garden Grove, California, United States | Recruiting |
| Kadima Neuropsychiatry Institute | La Jolla, California, United States | Recruiting |
| Open Mind Therapeutics | San Francisco, California, United States | Recruiting |
| TRIP Clinic at Psychedelic Science Institute | Santa Monica, California, United States | Recruiting |
| Innovative Clinical Research, Inc. | Lauderhill, Florida, United States | Recruiting |
| University of South Florida | Tampa, Florida, United States | Recruiting |
| Atlanta Center for Medical Research | Atlanta, Georgia, United States | Recruiting |
| CenExel iResearch, LLC | Decatur, Georgia, United States | Recruiting |
| Uptown Research Institute | Chicago, Illinois, United States | Recruiting |
| Henry Ford Medical Center - Columbus | Novi, Michigan, United States | Recruiting |
+ 10 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.